Moderna (MUN:0QF) - Stock Price, News & Analysis

0QF Stock Overview

0QF fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 77.2% below our estimate of its fair value

Revenue is forecast to grow 13.61% per year

Risk Analysis

Volatile share price over the past 3 months

Significant insider selling over the past 3 months

Moderna, Inc. Competitors

MorphoSys

XTRA:MOR

€2.6b

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€709.9m

Bayer

XTRA:BAYN

€25.8b

Price History & Performance

Summary of all time highs, changes and price drops for Moderna
Historical stock prices
Current Share Price	US$98.02
52 Week High	US$132.54
52 Week Low	US$64.86
Beta	1.59
1 Month Change	3.39%
3 Month Change	0.36%
1 Year Change	-24.53%
3 Year Change	-29.72%
5 Year Change	n/a
Change since IPO	474.22%

Recent updates

Shareholder Returns

	0QF	DE Biotechs	DE Market
7D	-5.2%	-4.3%	-2.5%
1Y	-24.5%	-19.4%	-0.4%

Return vs Industry: 0QF underperformed the German Biotechs industry which returned -15.8% over the past year.

Return vs Market: 0QF underperformed the German Market which returned 1% over the past year.

Price Volatility

Is 0QF's price volatile compared to industry and market?
0QF volatility
0QF Average Weekly Movement	9.1%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	9.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 0QF has not had significant price volatility in the past 3 months.

Volatility Over Time: 0QF's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2010	5,600	Stephane Bancel	www.modernatx.com

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.

Moderna, Inc. Fundamentals Summary

How do Moderna's earnings and revenue compare to its market cap?
0QF fundamental statistics
Market cap	€37.34b
Earnings (TTM)	-€4.43b
Revenue (TTM)	€6.43b

5.8x

P/S Ratio

-8.4x

P/E Ratio

Is 0QF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QF income statement (TTM)
Revenue	US$6.85b
Cost of Revenue	US$9.54b
Gross Profit	-US$2.69b
Other Expenses	US$2.02b
Earnings	-US$4.71b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 02, 2024

Earnings per share (EPS)	-12.31
Gross Margin	-39.28%
Net Profit Margin	-68.84%
Debt/Equity Ratio	0%

How did 0QF perform over the long term?

See historical performance and comparison

0QF Stock Overview

Rewards

Risk Analysis

Moderna, Inc. Competitors

XTRA:MOR

€2.6b

XTRA:BIO3

€1.4b

XTRA:FYB

€709.9m

XTRA:BAYN

€25.8b

Price History & Performance

Recent News & Updates

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

New major risk - Share price stability

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Recent updates

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

New major risk - Share price stability

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold €2.2m worth of stock

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: US$9.53 loss per share (vs US$2.67 profit in 3Q 2022)

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Investor sentiment deteriorates as stock falls 17%

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Investor sentiment improves as stock rises 20%

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$3.62 loss per share (vs US$5.55 profit in 2Q 2022)

Merck and Moderna, Inc. Initiate Phase 3 Study Evaluating V940 (Mrna-4157) in Combination with Keytruda(R) (Pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage Iib-Iv) Melanoma

Moderna, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Moderna Announces Global Regulatory Submissions for its Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345

Moderna, Inc. Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Growth Index

Moderna, Inc. Completes Submission of A Regulatory Application to the U.S. Food and Drug Administration for Its Updated COVID-19 Vaccine Containing Spike Proteins for the XBB.1.5 Sublineage of SARS-CoV-2

Moderna and Merck Announces mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

First quarter 2023 earnings released: EPS: US$0.20 (vs US$9.10 in 1Q 2022)

Full year 2022 earnings released: EPS: US$21.22 (vs US$30.28 in FY 2021)

Investor sentiment deteriorates as stock falls 15%

Moderna, Inc. Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate

Moderna, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

Moderna, Inc. (NasdaqGS:MRNA) entered into a definitive agreement to acquire OriCiro Genomics, Inc for $85 million.

Investor sentiment deteriorated over the past week

Chantal Friebertshäuser Joins Moderna, Inc. as Senior Vice President of Commercial - Europe, Middle East and Canada, Effective January 1, 2023

Moderna, Inc. and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

Investor sentiment improved over the past week

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

Moderna, Inc. Announces Executive Changes

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

Moderna, Inc. Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

Third quarter 2022 earnings released: EPS: US$2.67 (vs US$8.25 in 3Q 2021)

Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222

Investor sentiment improved over the past week

EMA Recommends Authorization of Moderna Vaccine

Moderna, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Merck and Moderna, Inc. Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine

Moderna, Inc. Announces Management Changes

European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

Shareholder Returns